The molecular pathogenesis of multiple myeloma
Niccolò Bolli1,2, Giovanni Martinelli3, Claudio Cerchione3
1Department of Oncology and Hemato- Oncology, University of Milan, Italy.
Hematology Reports
|January 7, 2021
Summary
Multiple Myeloma (MM) arises from B-lymphocytes with genomic alterations. Understanding MM progression, from early stages to symptomatic disease, is crucial for patient risk stratification and targeted therapies.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Multiple Myeloma (MM) involves uncontrolled plasma cell proliferation in bone marrow.
- The cell of origin is a B-lymphocyte with genomic aberrations acquired during germinal center reactions.
- The precise genetic events driving MM transformation and progression remain under investigation.
Purpose of the Study:
- To review the molecular pathogenesis of Multiple Myeloma.
- To discuss MM development from cell of origin through asymptomatic and symptomatic stages.
- To explore the role of genetic heterogeneity in MM recurrence and propose future interventions.
Main Methods:
- This is a review article, synthesizing existing research.
- The review discusses the developmental stages of Multiple Myeloma.
- It examines genetic heterogeneity and its impact on disease progression.
Main Results:
- Multiple Myeloma originates from B-lymphocytes with genetic alterations during germinal center reactions.
- Asymptomatic stages include monoclonal gammopathy of undetermined significance and smoldering MM.
- Genetic heterogeneity is a key driver of MM recurrence.
Conclusions:
- A comprehensive understanding of MM pathogenesis is vital for early diagnosis and risk stratification.
- Knowledge of molecular pathways can inform future diagnostic and therapeutic strategies for MM.
- Personalized treatment approaches based on genetic profiles may improve outcomes for MM patients.
More Related Videos
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
13.3K
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
6.7K
Related Concept Videos
02:07Tumor Progression
6.9K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.9K
02:23Abnormal Proliferation
4.9K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
01:31The Intrinsic Apoptotic Pathway
7.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.5K
01:15Differentiation of Common Myeloid Progenitor Cells
3.6K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.6K
03:03mTOR Signaling and Cancer Progression
4.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.1K
02:30Metastasis
6.1K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.1K